May 28, 2021

Announcements

Yale Cancer Center and Smilow Cancer Hospital Town Halls
Please plan to join the leadership of Yale Cancer Center and Smilow Cancer Hospital the first Thursday of each month at 5pm for our newly reconfigured research and clinical community town hall meetings. We encourage attendance from our Cancer Center membership, Smilow clinical providers and teams, and all staff. Topics to be discussed this month include COVID-19 Research at Yale, the Clinical Trials Office, Radiation Oncology, Clinical Operations and Research Updates, and Cancer Survivorship. At the conclusion of the June 3 Town Hall, a survey will launch to engage your feedback and suggestions for future Town Hall meetings. Please participate so we can ensure these forums meet the needs of our community.

Calendar details for Thursday, June 3 at 5pm

Isaac Y. Kim, MD, PhD, MBA, Named Chair of the Department of Urology
We are pleased to announce Isaac Y. Kim, MD, PhD, MBA, has been appointed Chair of the Department of Urology at Yale School of Medicine and Chief of Urology at Yale New Haven Hospital, effective September 1, 2021. A surgeon-scientist with more than a decade of leadership experience, Dr. Kim is currently Professor and Chief of the Division of Urology in the Department of Surgery at Rutgers Robert Wood Johnson Medical School; Chief of the Section of Urologic Oncology and Executive Director of the Prostate Cancer Center at Rutgers Cancer Institute of New Jersey; and Medical Director of Robotic Surgery at Monmouth Medical Center.

Dr. Kim spearheaded the development of the robotic surgery program

from the desk of Nita Ahuja, MD, MBA, FACS
Interim Director, Yale Cancer Center
Interim Physician-in-Chief, Smilow Cancer Hospital

News Center

Bernard G. Forget Hematology Scholars Program Supported by Friends who Give

Yale Cancer Center Among Top U.S. Cancer Centers Calling for Urgent Action to Get Cancer-
Dr. Kim spearheaded the development of the robotic surgery program at RWJ University Hospital and is an expert in robot-assisted radical prostatectomy, with more than 2,100 cases to date. He manages a basic science research program on the mechanism of prostate cancer treatment resistance and is investigating new therapeutic options for castration-resistant prostate cancer by developing Proteolysis Targeting Chimera (PROTAC) molecules for commercial translation. He also is active in clinical research, serving as the principal investigator of two clinical trials on advanced and metastatic prostate cancer. He helped establish a research consortium of more than 25 institutions from five countries to investigate the therapeutic role of cytoreductive radical prostatectomy in metastatic prostate cancer.

Dr. Kim received his doctorate from the Integrated Graduate Program in Tumor Cell Biology at Northwestern University Graduate School and his medical degree from the Feinberg School of Medicine at Northwestern University. He completed his residency in urology at Baylor College of Medicine, a research fellowship in urologic oncology at the National Cancer Institute, and a clinical fellowship in laparoscopy and endourology at the University of California, Irvine. He joined the faculty at Rutgers Robert Wood Johnson Medical School and Rutgers Cancer Institute of New Jersey in 2005. In 2017, he received his MBA in finance from the Wharton School at the University of Pennsylvania.

Yale Cancer Center and Smilow Cancer Hospital faculty will participate virtually in the 2021 ASCO Annual Meeting beginning next Friday, June 4 through educational sessions, panel discussions, poster sessions, and poster discussion sessions.

Special congratulations to Michael Grant, MD, and Benjamin Lu, MD, hematology/medical oncology fellows, and Daniel X. Yang, MD, a resident in therapeutic radiology, who have each been awarded Young Investigator Awards by the Conquer Cancer, the ASCO Foundation. “I am thrilled to see our trainees receiving these prestigious awards. It speaks to our efforts to promote our mentorship activities to pair trainees and fellows with advisors and projects early in their tenure,” said Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), Chief of Medical Oncology, and Associate Cancer Center Director for Translational Research.

If you plan to attend the meeting online, please login to support your colleagues at the meeting. A list of Yale participation is available online.

Mariya Rozenblit, MD, Appointed Instructor of Medicine (Medical Centers Calling for Urgent Action to Get Cancer-Preventing HPV Vaccination Back on Track

Read More

Skin Cancer Warning Signs, Risk Factors and Prevention Tips

Read More

Cancer Care Key to Hospital Expansion

Read More

Looking Forward Program at Smilow Cancer Hospital

Watch Now

Dr. Nunez-Smith Leads First Task Force on Health Equity
Mariya Rozenblit, MD, has been appointed an Instructor of Medicine (Medical Oncology) at Smilow Cancer Hospital and Yale Cancer Center and will care for patients with breast cancer beginning on July 1. Dr. Rozenblit is completing her Fellowship in Medical Oncology-Hematology at Yale and received her medical degree from Icahn School of Medicine at Mount Sinai. In 2020, she was the recipient of the ASCO Conquer Cancer Foundation Young Investigator Award for her project, "Using single nucleotide variants of high functional importance to predict the risk of developing breast cancer in young women with high-risk family history."

Under the mentorship of Dr. Lajos Pusztai during her fellowship, Dr. Rozenblit worked to compare PD-L1 protein expression in primary tumors versus metastatic lesions in triple negative breast cancers. This manuscript was published in the Journal for ImmunoTherapy of Cancer. She also has an interest in outcomes research, and under the mentorship of Dr. Sarah Mougalian evaluated the practice patterns and efficacy of everolimus and exemestane following prior hormone therapy and CDK4/6 inhibitor use in hormone positive metastatic breast cancer. This manuscript was published in Breast Cancer Research.

Upcoming CME Programs
Yale Cancer Center and Smilow Cancer Hospital are sponsoring several upcoming CME programs. Please register to hear your colleagues present, and share these opportunities with community physicians and other contacts.

June 18 at 12pm: Yale Breast Cancer CME Seminar: Imaging, Reconstruction, and Radiation Oncology
Register

June 25 at 8am: Yale’s Review of Advances in Oncology: Highlights from ASCO
Register

Notables
Iris Isufi, MD, has been promoted to Associate Professor of Medicine (Hematology). Dr. Isufi’s appointment is recognition of her dedication to providing the best patient care, to educating our trainees, and to advancing knowledge.

May is Brain Tumor Awareness Month, and our Chênevert Family Brain Tumor Center is an internationally-recognized lead center for comprehensive and multidisciplinary brain tumor care and a hub of excellence in clinical care and research. Our team of specialists, led by Clinical Program Leaders Jennifer Moliterno, MD, FAANS, and Antonio Omuro, MD, is dedicated exclusively to the care of patients with all types of brain tumors. Our Center’s expertise covers all the critical components to successfully care for patients with brain tumors, starting with comprehensive diagnostic evaluation and state-of-the-art genomic profiling of the tumor, and providing the latest treatment options and cutting-edge clinical trials. Our intraoperative MRI suite, one of the few in the world and the only in the state of Connecticut, features a powerful MRI that allows neurosurgeons to take real time images during the operation.
Vincent T. DeVita, Jr., MD, Amy and Joseph Perella Professor of Medicine (Medical Oncology), has been named to the Honorary Host Committee of the Nixon National Cancer Conference. The Conference is planned for December 1 and 2, 2021, to commemorate the fiftieth anniversary of the National Cancer Act at the Richard Nixon Presidential Library and Museum in Yorba Linda, California. The two-day meeting of experts will examine the past, present and future of cancer treatment and research.

Joan A. Steitz, PhD, Sterling Professor of Molecular Biophysics and Biochemistry, and a Howard Hughes Medical Institute investigator, is one of two recipients of the 2021 Warren Alpert Foundation Prize, which recognizes people whose scientific achievements have led to the prevention, cure or treatment of human diseases or disorders, and/or whose research constitutes a seminal scientific finding that holds great promise of ultimately changing our understanding of or ability to treat disease.

Congratulations to Ruth Halaban, PhD, Senior Research Scientist in Dermatology and a member of Yale Cancer Center’s Genetics, Genomics, and Epigenetics Research Program, on receiving a Melanoma Research Alliance Established Investigator Award to research targeted therapy of melanoma with LZTR1 and CRKL inhibitors.

Lilian Kabche, PhD, Assistant Professor of Molecular Biophysics and Biochemistry and a member of Yale Cancer Center’s Radiobiology and Radiotherapy Research Program, and Sidi Chen, PhD, Associate Professor of Genetics and a member of Yale Cancer Center’s Genetics, Genomics, and Epigenetics Research Program, have each been awarded the 2021 Pershing Square Sohn Prize for Young Investigators in Cancer Research, a prestigious award from the Pershing Square Sohn Cancer Research Alliance. They will each receive $200,000 per year for three years to support their research.

Congratulations to Barbara Burtness, MD, Professor of Medicine (Medical Oncology), on her appointment as Chair of the Task Force on Advancement for Women for the ECOG-ACRIN Oncology Research Group. Thank you for your service, Dr. Burtness!

Shalin Kothari, MD, Assistant Professor of Medicine (Hematology) and a member of Yale Cancer Center’s Cancer Signaling Networks Research Program, has been named to the Lymphoma Research Foundation’s Mantle Cell Lymphoma Consortium (MCLC).

Lieping Chen, MD, PhD, United Technologies Professor of Cancer Research, Professor of Immunobiology, Medicine (Medical Oncology) and Dermatology, and co-leader of the Cancer Immunology Program at Yale Cancer Center, has been appointed as a visiting professor of cancer immunotherapy by the Oxford Branch of the Ludwig Institute for Cancer Research.

The winners of this year’s Fourth Annual Yale Cancer Center Trainee Colloquium Research Excellence Prize Awards were:

- Dr. Carla Rothlin discusses new immunotherapy research, and strategies to advance cancer treatment options, on Yale Cancer Answers on Connecticut Public Radio, WNPR. Join Dr. Rothlin online, or download our podcast from iTunes this week.

- Dr. Jennifer Moliterno's new book, "Parker's Water Tube Ride," and announce that the Parker Book Series is available for free to families navigating a diagnosis of a brain tumor. This week over 500 copies of the Parker Book Series were delivered to 26 children's hospitals nationwide thanks to the support of The Childrens Brain Tumor Foundation, the Lovemark Foundation, and the Susan Beris, MD Fund for the Yale Brain Tumor Surgery.
A Hypoxia-Driven Transcriptional Program Characterizes Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. Camila Robles-Oteiza, PhD Candidate, Immunobiology, Mentor: Katerina Politi, PhD

Impact of Hematology Electronic Consultations on Referring Clinician Practices and Patient Outcomes at Veterans Affairs Connecticut Healthcare System. Talib Dosani, MD, Clinical Fellow, Hematology and Medical Oncology, Mentor: Michal Rose, MD

KMT2D Deficiency Sensitizes Tumors to Immune Checkpoint Blockade. Ryan Chow, MD-PhD Candidate, Genetics, Mentor: Sidi Chen, PhD

Neoantigen-Driven B cell and CD4+ T Follicular Helper Cell Collaboration Promotes Robust Anti-Tumor CD8+ T Cell Responses. Can Cui, PhD Candidate, Immunobiology, Mentors: Nikhil Joshi, PhD, and Joseph Craft, MD

Three Yale Cancer Center members were awarded 2021 Blavatnik Awards during an award ceremony at the Yale Innovation Summit:
- Net Therapeutics: Targeting NETs in Human Disease. Demetrios Braddock, MD, PhD, Associate Professor of Pathology.
- Apira: Developing Therapeutic OST Inhibitors. Joseph Contessa, MD, PhD, Professor of Therapeutic Radiology and Pharmacology.
- TargetGene Therapeutics: Direct Targeting of Amplified Cancer Driver Genes as a Therapeutic Strategy. Faye Rogers, PhD, Associate Professor of Therapeutic Radiology.

Julia Foldi, MD, Mariya Rozenblit, MD, and Janie Zhang, MD, fellows in the hematology/medical oncology fellowship program, have been accepted to the 2021 ASCO/AACR Methods in Clinical Cancer Research Workshop to study the essentials of effective clinical trial design.

Employee Profile: Gail Anderson

When a patient signs on for a clinical trial, there are many steps involved before they even receive the trial drug. Gail Anderson, Clinical Research Associate (CRA) for the Melanoma and Renal Cell Carcinoma Disease Team in the Yale Cancer Center Clinical Trials Office (CTO), is their initial contact and helps to schedule the various tests they need to confirm they are eligible. It is a busy, non-stop role as she helps to manage clinical trial participation for 23-25 patients at a time.

Gail is also responsible for coordinating patient visits with the research team, ensuring that all necessary paperwork is completed, and providing support for the patient and their family throughout the process. Her expertise and dedication play a crucial role in ensuring the success of clinical trials and the well-being of patients participating in them.

We congratulate Jill Lacy, MD, Professor of Medicine (Medical Oncology) and Ronald Salem, MD, FACS, Lampman Professor of Surgery (Surgical Oncology), who were awarded Yale Medicine Distinguished Clinical Career Awards. The award was created by the Yale Medicine Board to “recognize and honor the careers of physicians marked by significant accomplishments, exemplary dedication, and important contributions in advancing Yale Medicine, the overall medical profession, and the community.”

Dr. Lacy’s clinical practice is devoted to caring for patients with gastrointestinal malignancies. She is the principal investigator on clinical trials for in gastrointestinal malignancies, including gastroesophageal, pancreatic, and colorectal cancers. She was recently named a Fellow of the American Society of Clinical Oncology.

Dr. Salem, a renowned expert in pancreatic and gastrointestinal cancers, has led surgical oncology at Yale since 1996. As Division Chief in the Department of Surgery and Chief of Surgical Oncology at Smilow Cancer Hospital, the division has grown to include destination sites across the state and more than 17 physicians leading programs in Breast Surgery, Hepato-Pancreato-Biliary Surgery, and Endocrine Surgery.
Gail is also responsible for tracking the data from the study for each patient and entering it into Electronic Data Capture (ED) and making sure the study sponsor has all the required data. She talks with every patient and schedules them for scans and appointments. "I like to get to know each patient as much as possible, and learn about their schedule, if they have transportation issues, and what time of day is most convenient for them to come in for appointments. I want to make the process as easy as possible for them, as they are the most important part of any study. Without them, this wouldn’t be possible," said Gail.

Gail started as a temp almost nine years ago and enjoys working as part of a cohesive team. In a position with lots of moving parts, everyone is willing to help out when needed. "It is always exciting when a new study opens, but it is even more exciting when a drug actually gets approved for use," commented Gail.

Gail was recently recognized for a Yale Cancer Center and Smilow Cancer Hospital’s #OUTOFTHEBLUETHANKS after stepping up to help with scheduling and making calls to patients to improve patient satisfaction for a protocol outside of her assigned work. In addition, Gail has been working diligently in preparation for an upcoming FDA audit. Gail has happily volunteered for additional tasks to confirm audit readiness, has implemented a standard binder set up to confirm uniformity of documents, and is always the first person to say, ‘What can I do to help?’ The team will be audit ready primarily due to Gail’s efforts.

Barbara Johnson, Clinical Research Coordinator in the CTO commented, “Gail is always ready to jump in and help regardless of the tasks on her plate already. She just does it because ‘it needs to be done.’ Her attention to detail and organizational skills are phenomenal. There have been times when we have adjusted processes to align with her personal processes due to increased efficiency, and the patient is always her main priority. She recognizes their struggles and acts accordingly.”

Recent Publications


Read More

Congratulations to Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C), Professor of Surgery (Oncology) and a member of the Cancer Prevention and Control Research Program at Yale Cancer Center, who was named a Fellow of the American Society of Clinical Oncology (FASCO).

Anees Chagpar, MD, MBA, MPH, FACS, FRCS(C), named Fellow of the American Society of Clinical Oncology (FASCO)

Clinical Trials Day was created to recognize the first the launch of the randomized clinical trial on May 20, 1747 when surgeon mate James Lind suspected that the devastating scurvy outbreak on the HMS Salisbury of Britain’s Royal Navy fleet could be cured through the introduction of acids. Lind recruited 12 men and conducted what many refer to as the first clinical trial.

In the 274 years since, standards and science have come a long way! With a rich history of drug discovery and development at Yale, our physicians and scientists are finding new ways to treat cancer.

Read More
and scientists are finding new ways to beat cancer and to give our patients renewed hope. Yale is home to some of the world’s leading investigators in cancer, and their knowledge and research delivers new therapies and advances in patient care at Smilow Cancer Hospital and at our Care Centers.

Thanks to the incredible efforts of our researchers and Clinical Trials team, we offer clinical trials to our patients in all disease areas, including Phase I clinical trials for advanced and metastatic disease. Today, we salute and say thank you to all of our physicians, scientists, clinical research associates, nurses, and staff who work countless hours to advance science and bring effective therapies to our patients, and our patients who participate in clinical trials!

Bladder cancer is the 6th most common cancer in the United States according to statistics from the National Institutes of Health. Our Bladder Cancer Team is at the forefront of bladder cancer treatment, integrating innovative approaches and the latest technology to provide superior patient care. Our goal is to provide the safest and most effective treatment available and thanks to groundbreaking research and clinical trials, we are working to help patients live the longest possible time with the best quality of life.

Moore, J. L., & Greco, V. 
*Functional cell death, corneoptosis, requires temporally controlled intracellular acidification.*

*Proceedings of the National Academy of Sciences of the United States of America, 118*(22), e2106633118.

Read More

Sutton TL, Walker BS, Billingsley KG, Sheppard BC, Corless CL, Heinrich MC, Mayo SC

*Disease-Free Interval is Associated with Oncologic Outcomes in Patients with Recurrent Gastrointestinal Stromal Tumor* 

*Annals of Surgical Oncology, Online ahead of print.*

Read More


*BMJ Open, 11*(5), e048863.

Read More

Mittal A, Wang M, Vidyarthi A, Yanez D, Pizzurro G, Thakral D, Tracy E, Colegio OR.

*Topical Arginase Inhibition Decreases Growth of Cutaneous Squamous Cell Carcinoma.* 

*Scientific Reports, 11*(1):10731.

Read More


*Circulation, Online ahead of print.*

Read More

Cheraghlou S, Sadda P, Agogo GO, Girardi M.

*A Machine-Learning Modified CART Algorithm Informs Merkel Cell Carcinoma Prognosis.* 

*Australasian Journal of Dermatology, Online ahead of print.*

Read More

Sule A, Van Doorn J, Sundaram RK, Ganesa S, Vasquez JC, Bindra RS.

*Targeting IDH1/2 Mutant Cancers with Combinations of ATR and PARP Inhibitors.* 

*NAR Cancer, 3*(2), zcab018.

Read More
Clinical Imaging, 78, 194-200, Online ahead of print.
Read More

Cell Host & Microbe, S1931-3128(21), 00190-6, Online ahead of print.
Read More

Journal of Clinical Oncology, JCO2100831, Online ahead of print.
Read More

Zuo L, Wijegunawardana D. Redox Role of ROS and Inflammation in Pulmonary Diseases. 
Advances in Experimental Medicine and Biology, 1304, 187-204.
Read More

Archives of Pathology and Laboratory Medicine, Online ahead of print.
Read More

Human Vaccines and Immunotherapeutics, 1-6, Online ahead of print.
Read More

Fogel AL, Lacktman NM, Kvedar JC. Skin Cancer Telemedicine Medical Malpractice Risk. 
JAMA Dermatology, Online ahead of print.
Read More

Annals of Surgical Oncology, Online ahead of print.
Read More
**Single-cell Multiomics Dissection of Basal and Antigen-specific Activation States of CD19-Targeted CAR T Cells.**
*Journal for ImmunoTherapy of Cancer, 9*(5), e002328.

Read More

Yasin F, Chow R, Emu B, Bui T, Prsic E. 
**Palliation of Malignancies in HIV Infection.**
*BMJ Supportive & Palliative Care, bmjspcare-2021-003179, Online ahead of print.*

Read More

Lokeshwar SD, Klaassen Z, Saad F. 
**Treatment and Trials in Non-metastatic Castration-resistant Prostate Cancer.**
*Nature Reviews Urology, Online ahead of print.*

Read More

**Pharmacological Inhibition of PI5P4Kα/β Disrupts Cell Energy Metabolism and Selectively Kills p53-null Tumor Cells.**
*Proceedings of the National Academy of Sciences of the United States of America, 118*(21), e2002486118.

Read More

Bai Z, Su G, Fan R. 
**Single-cell Analysis Technologies for Immuno-oncology Research: from Mechanistic Delineation to Biomarker Discovery.**
*Genomics, Proteomics & Bioinformatics, S1672-0229*(21), 00077-2, Online ahead of print.

Read More

Loomba R, Friedman SL, Shulman GI. 
**Mechanisms and Disease Consequences of Nonalcoholic Fatty Liver Disease.**
*Cell, 184*(10), 2537-2564.

Read More

Moutafi M, Rimm DL. 
**Putting the Microenvironment into the Immunotherapy Companion Diagnostic.**
*Clinical Cancer Research, clincanres.1238.2021, Online ahead of print.*

Read More

---

**Calendar**

- Tune in now to learn more about Genetic Counseling with the @SmilowCancer Hospital Genetic Counseling team for "#GeneticCounselor for a Day!"
- Dr. Suchitra Krishnan-Sarin @YalePsych and @YaleCancer #Cancer Prevention and Control Program, discusses a new program aimed at helping teenagers addicted to #ecigarettes and #vaping on @WTNH
- Interested in learning more about Epigenetic Changes in Aging and #Cancer? Log in to virtual #AACR21 today at 2:16 to hear a special presentation from @DrMorganLevine
- @YaleCancer scientists and physicians join #thenci-designated cancer centers across the U.S. to urge parents to get their kids vaccinated against #HPV
- 34 million U.S. adults smoke & daily, 2,000 kids smoke their first cigarette. At 2pm @DrRoyHerbstYale and @KrishnanSarin join the @AACR #Tobacco Policy Subcommittee to discuss the leading cause of preventable death in the U.S.
- In a special session at #AACR21 today at 9:45am, @DrRoyHerbstYale discusses the backstory concerning the @US_FDA approval of Osimertinib for #lungcancer treatment.
- “Our findings reinforce the importance of getting vaccinated.”—Dr. Akiko Iwasaki @VirusesImmunity on new @nresearchnews w/@aaronmring @Eric_Y_wang showing rogue antibodies damage cells & tissue in #COVID19 patients.
- Congratulations to .@YaleCancer scientists @SidiChen and Dr. Lillian Kabeche @KabecheLab on receiving the prestigious #PSSCRA21 Pershing Square Sohn Prize for Young Investigators in Cancer Research
- Ready to learn more about the Center for #GastrointestinalCancers @SmilowCancer @YaleCancer? Log in at Noon today for our virtual Grand Rounds presented by @PamelaKunzMD & Dr. Mandar Muzumdar

Funding and Award Opportunities

AACR Research Funding Opportunities
The AACR, in collaboration with its scientific and funding partners, offers a variety of research grant mechanisms for researchers worldwide at all career levels
- Clinical Oncology Research (CORE) Training Fellowships: Application Deadline - May 31, 2021
- MPM Oncology Charitable Foundation Transformative Cancer Research Grants: LOI Deadline - June 29, 2021
- Lobular Breast Cancer Alliance Invasive Lobular Carcinoma Research Fellowship: LOI Deadline - July 6, 2021

Breast Cancer Alliance Young Investigator Grant
To encourage a commitment to breast cancer research, the BCA invites clinical doctors and research scientists whose primary focus is breast cancer and who are in the early stages of their careers to apply for funding for the Young Investigator Grant.

Internal LOI Deadline: June 1, 2021

The Cure Starts Now Foundation Research Grants
Research questions considered - Disease Impact: Does the study propose an intervention or clinical tool that will reduce the morbidity or mortality from or potentially find a cure for pediatric brain cancer?
Innovation: Does the research study propose a novel approach or represent advancement in current treatment of pediatric brain cancer?

Application Deadline: June 1, 2021

Cancer Prevention, Detection, Diagnosis, and Treatment Technologies for Global Health (U01)
This FOA supports the development of cancer-relevant technologies suitable for use in low- and middle-income countries.

Application Deadline: June 2, 2021

Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program
The BMSF DCTCDP is a 2-year program designed to support the career development of early-stage investigator (as defined by NIH) physicians underrepresented in medicine, or physicians who have a demonstrated commitment to increasing diversity in clinical research, to become independent clinical trial investigators who are engaged in high-quality research and committed to contributing to the development of novel treatment strategies.

Smilow Cancer Hospital and Yale Cancer Center
to become independent clinical trial investigators who are engaged in advancing health equity through their research and mentoring.

Application Deadline: July 2, 2021
Read More

Short Courses on Innovative Methodologies and Approaches in the Behavioral and Social Sciences (R25)
The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.

Application Deadline: June 4, 2021
Read More

Emerson Collective: Digital Oncology Care
This RFP invites grant applications for solutions that implement evidence-based research findings to improve patient health outcomes for clinical practice in oncology. Interested applicants should contact Tammy Wu for institutional guidelines.

Application Deadline: June 8, 2021
Read More

The NCI Transition Career Development Award
- **K22 - Independent Clinical Trial Required** - This FOA represents the continuation of an NCI program to facilitate the transition of investigators in mentored, non-independent cancer research positions to independent faculty cancer research positions. Application Deadline: June 12, 2021 Read More
- **K22 - Independent Clinical Trial Not Allowed** - This FOA is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Application Deadline: June 12, 2021 Read More
- **K22 Independent Basic Experimental Studies with Humans Required** - This FOA is designed specifically for basic science experimental studies involving humans. Application Deadline: June 12, 2021 Read More

Building Interdisciplinary Research Careers in Women’s Health Program K12
This Program will support mentored research career development of junior faculty members, known as BIRCWH Scholars, who have recently completed clinical training or postdoctoral fellowships, and who will be engaged in interdisciplinary basic, translational, behavioral, clinical, and/or health services research relevant to the health of women and, where appropriate, the use of both sexes to better understand the influence of sex as a biological variable on health and disease.

Application Deadline: June 11, 2021
Read More

Administrative Supplements to Stimulate and Strengthen Global Cancer Survivorship Research
This NOSI is to announce an opportunity for supplemental funding to active, eligible NCI-funded grants and cooperative agreements to:

Smilow Cancer Hospital and Yale Cancer Center Clinical and Research Town Hall
June 3; 5:00 PM
Daniel DiMaio, MD, PhD | Akiko Iwasaki, PhD | Nathan Grubaugh, PhD | Roy S. Herbst, PhD | Lynn Wilson, MD, MPH | Kevin Billingsley, MD, MBA | Kim Slusser, MSN, RN | Tara Sanft, MD
Learn More

Yale Cancer Answers
June 6; 7:30 PM
NPR
Colon and Rectal Surgery
Amit Khanna, MD
Learn More

Stem Cell Center Spring Seminar Series
June 7; 2:00 PM
Stem Cells in the Adult Brain: Regulation and Diversity
Fiona Doetch
Learn More

Yale New Haven Hospital Auxiliary Presents
June 7; 7:00 PM
Looking Forward Virtual Fashion Show
Learn More

Bereavement Workshop
June 8; 9:30 AM
Adults Grieving the Death of a Parent
Learn More

Yale Cancer Center Grand Rounds
June 8; 12:00 PM
Prostate and Urologic Cancers Disease Aligned Research Team
Daniel P. Petrylak, MD
Learn More

Yale Systems Biology Institute and Center for Cancer Systems Biology Present Symposium 2021
June 8; 1:00 PM
Coming of Age in the New Age – Day 1
Learn More

Advances in the RNA biology of SARS-CoV-2 at Yale
June 8; 2:00 PM
Learn More

Digestive Diseases Research Seminar Series
June 8; 5:00 PM
Pamela Kunz, MD
Learn More

Smilow Shares 2021 Survivorship Series
June 8; 7:00 PM
active, eligible NCI-funded grants and cooperative agreements to support global cancer survivorship research.

**Application Deadline:** June 11, 2021

Read More

**YCC 2021 Internal Pilot Awards Program**
These grants will support all potential areas of innovative cancer research including basic, clinical, computational, population and epidemiology, prevention/control, implementation science and translational cancer research.

**Application Deadline:** June 15, 2021

Read More

**Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed)**
This FOA is a continuation of an NCI program to enhance the diversity of the pool of the cancer research workforce by recruiting and supporting eligible New Investigators and Early Stage Investigators from diverse backgrounds, including from groups that have been shown to be nationally underrepresented in the biomedical, behavioral, clinical and social sciences.

**Application Deadline:** June 15, 2021

Read More

**DoD Kidney Cancer Awards**
- Idea Development Award- Letter of Intent Due: June 15, 2021
- Concept Award- Letter of Intent Due: June 22, 2021
- Post-doc/Clinical Fellow Award- Letter of Intent Due: June 22, 2021
- Translational Award - Letter of Intent Due: June 15, 2021

Read More

**Emerson Collective Cancer Research Fund**
This fund is to support individual or team proposals for research projects related to engineering allogeneic cells with new properties; validating new target antigens for cell therapy in cancer; targeted intracellular gene or protein delivery mechanisms; and enabling early cancer detection. Interested applicants should contact Tammy Wu for institutional guidelines.

**Application Deadline:** June 16, 2021

Read More

**NCI Clinical Proteomic Tumor Analysis Consortium (CPTAC)**
These FOAs support the NCI CPTAC managed by the Office of Cancer Clinical Proteomics Research (OCCPR). CPTAC leverages recent advancements in cancer proteomics and genomics to better understand the complexity between the proteome and the genome in cancer and accelerate research in these areas by disseminating resources for the scientific community.

- Proteome Characterization Centers (PCCs) for Clinical Proteomic Tumor Analysis Consortium (U24): **Application Deadline:** June 30, 2021
- Proteogenomic Data Analysis Centers (PGDACs) for Clinical Proteomic Tumor Analysis Consortium (U24): **Application Deadline:** June 30, 2021
- Proteogenomic Translational Research Centers (PTRCs) for Clinical Proteomic Tumor Analysis Consortium (U01): **Application Deadline:** July 30, 2021

Read More

Submissions
Please submit your recent publications, awards, and grant announcements to:

Renee Gaudette
Director, Public Affairs and Communications
2021 ALSF ‘A’ Award Grant
The ‘A’ Award is a four-year grant designed for independent, early career scientists who demonstrate a commitment to pediatric cancer research and have institutional support for their career development.

**Application Deadline:** June 18, 2021

Read More

NCCN/Pfizer Development of Talazoparib for Prostate Cancer RFP
This RFP is seeking proposals to advance the understanding of the mechanisms of action, underlying biology, and clinical activity of talazoparib in prostate cancer.

**Letter of Intent Due:** June 21, 2021

Read More

NCI Equity and Inclusion Program RFIs

- **Seeking Stakeholder Input on Enhancing Cancer Health Disparities Research:** This RFI is open to researchers, clinicians, academic institutions, healthcare and community organizations, and the public. Please follow the submission instructions in the RFI and submit your response by June 25, 2021.

- **Seeking Stakeholder Input on Enhancing Diversity and Inclusion in the Cancer Research Workforce:** This RFI is open to extramural grantees, staff and researchers in academic institutions and industry, federal employees, and the public. Please follow the submission instructions in the RFI and submit your response by July 15, 2021.

Read More

Gabrielle’s Angel Foundation
Gabrielle’s Angel Foundation remains committed to funding innovative, translational proposals and to supporting promising independent early-career investigators, rather than well-established, senior scientists.

**Letter of Intent Due:** June 27, 2021

Read More

3D Technologies to Accelerate HTAN Atlas Building Efforts (UH2)
Through this FOA, the NCI, as a part of its Beau Biden Cancer Moonshot Initiative, invites submission of applications requesting support for projects that will accelerate cancer research.

**Application Deadline:** June 30, 2021

Read More

SU2C Lung Cancer Health Equity Research Team Grant Program
This program seeks to address the issue of low participation by racial and ethnic minority populations in lung cancer research despite the disproportionate burden of disease in these groups through studies that inform clinical practice and evaluate approved regimens in special or expanded populations.

**Application Deadline:** July 1, 2021

Read More

Emergency Awards: Community-engaged COVID-19 Testing Interventions among Underserved and Vulnerable Populations

RADx-UP Phase II (U01 Clinical Trial Optional)
This FOA supports research and development activities at Biomedical Advanced Research and Development Authority (BARDA) for COVID-19 testing interventions among underserved and vulnerable populations.
This FOA uses an emergency U01 mechanism to support Phase II of the Rapid Acceleration of Diagnostics – Underserved Populations (RADxSM-UP) initiative. These two-year Testing Research Projects will (1) expand the scope and reach of RADxSM-UP testing interventions to reduce COVID-19 disparities among underserved and vulnerable populations and (2) address scientific questions on interventions to increase access and uptake of COVID-19 testing given the increasing availability of SARS-CoV-2 vaccines.

**Application Deadline:** July 7, 2021

Read More

**Emergency Award: RADx-UP - Social, Ethical, and Behavioral Implications (SEBI) Research on Disparities in COVID-19 Testing among Underserved and Vulnerable Populations (U01)**

The overarching goal of the RADx-UP initiative is to understand and ameliorate factors that have placed a disproportionate burden of the pandemic on underserved and/or vulnerable populations, specifically by implementing programs that expand the scope and reach of COVID-19 testing interventions to reduce these disparities.

**Application Deadline:** July 7, 2021

Read More

**DoD Ovarian Cancer Research Program Awards**
- Pilot Award - Application Deadline: July 8
- Proteogenomics Award - Application Deadline: July 8
- CDMRP Inv Initiated Award - Application Deadline: July 8
- Clin Translational Award - Application Deadline: July 8
- CDMRP Academy Award - Application Deadline: July 8
- CDMRP Omics Consortium Award - Application Deadline: July 8

Read More

**2021 ALSF Young Investigator Grant**

The Young Investigator Grant is a mentored career development award designed to support early career researchers, such as postdoctoral fellows, clinical fellows or instructors, striving to develop independent careers in pediatric cancer research.

**Application Deadline:** July 12, 2021

Read More

**Tobacco Regulatory Science (R01)**

The purpose of this FOA is to invite R01 applications to support biomedical and behavioral research that will provide scientific data to inform regulation of tobacco products to protect public health.

**Application Deadline:** July 14, 2021

Read More

**Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO) in Cancer Survivors Consortium (U01)**

Through this FOA, the NCI seeks to support exercise and/or medical nutrition intervention research designed to improve cancer treatment-related outcomes for therapies delivered with curative or life-extending intent to cancer survivors.

**Application Deadline:** July 14, 2021

Read More
Coordinating Center for Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO) in Cancer Survivors Consortium (U24)
Through this FOA, the NCI will support a Coordinating Center (CC) to facilitate coordination across the new Exercise and Nutrition Interventions to Improve Cancer Treatment-related Outcomes awardee sites.
**Application Deadline:** July 14, 2021
Read More

Centers on Telehealth Research for Cancer-Related Care (P50)
The purpose of this FOA is to fund P50 Centers dedicated to advancing a national telehealth research agenda focused on improving cancer-related care and outcomes across the cancer control continuum in a rapidly changing healthcare, policy, technology, and communication environment.
**Application Deadline:** July 20, 2021
Read More

Launching Future Leaders in Global Health (LAUNCH) Research Training Program (D43)
The purpose of this program is to provide opportunities for up to six consortia to develop or expand global health research training programs
**Application Deadline:** August 20, 2021
Read More